HHS Price Negotiations Could Be Delayed When Biologics Have Biosimilars Pending Under Bill
Executive Summary
Latest iteration of drug pricing legislation from Senate Democrats would also firm up the number of drugs HHS must choose for price negotiation each year and no longer treats insulin as a separate class for purposes of negotiation.
You may also be interested in...
What Exactly Is A ‘Small Biotech’? US Medicare Agency Will Try To Spell It Out
CMS’s new price negotiation authority has an exemption for ‘small biotech’ companies. The agency’s implementation plan suggests that will be a tricky concept to define.
Amgen Mvasi, Kanjinti Sales Decline As Biosimilars Industry Faces New Policy Challenges
ASP metric used in Medicare, and often in commercial insurance, for reimbursement of physician-administered drugs is an important factor in the sales arc for biosimilars. Price negotiations under IRA could bring their own margin-squeezing pain to pharmacy-benefit biosimilars.
Medicare Part B Payment Boost For Biosimilars A Positive Step But ‘More Must Be Done’
The policy is welcomed by biosimilar stakeholders, but amounts to a relatively small increase. To qualify for the revised payment, a biosimilar must have an average sales price that is less than its reference drug’s ASP and not all do.